Australian Pharma Stock News

Immutep (ASX:IMM) has jumped onto investors radar after two meaningful updates: a lucrative licensing deal with Dr. Reddy’s for its cancer immunotherapy efti, and fresh Phase II breast cancer data reinforcing its development pathway. See our latest analysis for Immutep. The recent licensing deal and upbeat breast cancer data appear to have flipped sentiment, with a 1 month share price return of 25.49 percent and a 90 day share price return of 36.17 percent standing in contrast to a still...

Elevra Lithium, formed from Sayona Mining’s acquisition of Piedmont Lithium, recently reported record production at its North American Lithium mine and outlined a brownfield expansion aimed at lifting output and lowering operating costs. The expiry and cessation of nearly 14,900 unexercised options subtly reshapes Elevra Lithium’s capital structure, highlighting management’s focus on operational performance over equity dilution. With those developments in mind, we’ll explore how record North...

In late November 2025, APA Group announced a special call to discuss its Joint Development Agreement with CS Energy to develop and own the proposed Brigalow Peaking Power Plant. This collaboration highlights APA Group’s push further into peaking power generation, potentially enhancing its role in supporting grid reliability alongside renewables. We’ll now explore how the Brigalow peaking power partnership with CS Energy may reshape APA Group’s existing investment narrative and risk...

As Australian shares prepare for a mid-week rise, the market remains attentive to interest rate decisions both locally and in the U.S., with investors weighing their options amidst economic uncertainties. In this context, penny stocks—though often seen as relics of past market trends—still capture attention for their potential to unlock growth in lesser-known corners of the market. By focusing on companies with strong financial health, investors can find opportunities that balance stability...

It is hard to get excited after looking at Volt Group's (ASX:VPR) recent performance, when its stock has declined 10.0...

Key Insights Insiders appear to have a vested interest in Mader Group's growth, as seen by their sizeable ownership...

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...

If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...

With the business potentially at an important milestone, we thought we'd take a closer look at Vitasora Health...

Key Insights Given the large stake in the stock by institutions, Orica's stock price might be vulnerable to their...

If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Firstly, we'd...

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

With the business potentially at an important milestone, we thought we'd take a closer look at Titomic Limited's...

Elixir Energy Limited ( ASX:EXR ) insiders who acquired shares over the previous 12 months, can probably afford to...

It might seem bad, but the worst that can happen when you buy a stock (without leverage) is that its share price goes...

In the current Australian market landscape, recent events such as the Reserve Bank of Australia's decision to hold interest rates steady have led to mixed reactions, with major indices experiencing fluctuations and sectors like real estate showing some resilience. Amidst these conditions, identifying undervalued stocks can be a strategic approach for investors seeking opportunities that may offer potential upside when market sentiments shift.

The Australian market recently experienced a brief surge following the Reserve Bank of Australia's decision to hold interest rates steady, though it settled into a slightly negative territory by the day's end. In such fluctuating conditions, identifying promising investments requires a keen eye for companies with strong financial foundations. Penny stocks, although an older term, remain relevant as they often represent smaller or newer companies that can offer unique opportunities for growth...

Artrya (ASX:AYA) has secured a three year commercial agreement to deploy its Salix platform across Northeast Georgia Health System, providing at least A$300,000 in revenue with additional potential from per scan fees. See our latest analysis for Artrya. The announcement appears to have accelerated an already powerful trend, with a 7 day share price return of 25.56 percent contributing to a 533.87 percent year to date share price return and a 727.37 percent 1 year total shareholder return...

Clinuvel Pharmaceuticals has recently expanded its Vallaurix research, development, and innovation hub in Singapore, backed by the Singapore Economic Development Board, to build a global center for advanced, long-acting peptide therapies and integrated formulation and analytical sciences. This move strengthens Clinuvel’s push toward greater vertical integration in peptide-based medicine, aiming to speed up late-stage development programs and broaden its pipeline beyond a single flagship...

When close to half the companies operating in the Healthcare industry in Australia have price-to-sales ratios (or...

With the Reserve Bank of Australia expected to maintain its current interest rate, Australian shares are experiencing another dip, influenced by overnight declines in major U.S. indices. Despite these broader market movements, opportunities still exist within specific sectors and stocks. Penny stocks—once a buzzword but now more of a niche—continue to offer growth potential by providing access to smaller or newer companies that may possess strong financial health and long-term prospects.

We feel now is a pretty good time to analyse Clarity Pharmaceuticals Ltd's ( ASX:CU6 ) business as it appears the...

When close to half the companies in Australia have price-to-earnings ratios (or "P/E's") below 21x, you may consider...

The recent price decline of 10% in Quantum Graphite Limited's ( ASX:QGL ) stock may have disappointed insiders who...